Apellis Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
APLS Apellis Pharmaceuticals Inc
JOBY Joby Aviation Inc
MYMD MyMD Pharmaceuticals Inc
RVLP RVL Pharmaceuticals PLC
PDO PIMCO Dynamic Income Opportunities Fund
BOCT Innovator U.S. Equity Buffer ETF™ October
BAC Bank of America Corp
YARIY Yara International ASA
XOM Exxon Mobil Corp
XLF Financial Select Sector SPDR® Fund
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. Its SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). The Company’s EMPAVELI (pegcetacoplan) is the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) is the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has an approval for the treatment of PNH in Saudi Arabia, Australia, and the United Kingdom. Systemic pegcetacoplan markets under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union and United Kingdom.

Premarket

Last Trade
Delayed
$38.89
-0.045 (-0.12%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$38.94
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
170

10-day average volume:
3,080,069
170
  • Prev Close
    38.94
  • Today's Open
    --
  • Day's Range
    --
  • Avg Vol (10-day)
    3.1M
  • Last (time)
    3:59p ET 10/03/23
  • Last (size)
    15
  • 52-Wk Range
    19.83 - 94.75
    LowHigh
  • (06/14/23 - 08/07/23)
    96.34%
  • 88.0%
  • Market Cap
    4.6B
  • Shares Outstanding
    117.7M
  • -5.84
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 1.0
  • 97.32
  • (% of float 09/15/23)
    13.51

Latest News

October 03, 2023
8:43 am ET
Zacks
October 02, 2023
12:27 pm ET
Globe Newswire
11:50 am ET
Accesswire
11:16 am ET
Globe Newswire
9:29 am ET
Accesswire
9:12 am ET
Accesswire
7:00 am ET
Globe Newswire
5:45 am ET
PR Newswire
2:02 am ET
Accesswire
October 01, 2023
8:48 pm ET
Accesswire
8:20 pm ET
Accesswire
8:01 pm ET
Accesswire
5:19 pm ET
Newsfile
5:00 pm ET
Newsfile
9:43 am ET
Accesswire
9:43 am ET
Globe Newswire
9:43 am ET
Accesswire
September 30, 2023
4:46 pm ET
Globe Newswire
September 29, 2023
10:50 pm ET
BusinessWire
9:00 pm ET
BusinessWire
7:16 pm ET
Newsfile
4:48 pm ET
Accesswire
4:28 pm ET
PR Newswire
4:28 pm ET
PR Newswire
2:02 pm ET
Accesswire
1:39 pm ET
BusinessWire
12:41 pm ET
Globe Newswire
10:15 am ET
Accesswire
10:00 am ET
Accesswire
2:32 am ET
Accesswire
2:31 am ET
Accesswire
12:02 am ET
Accesswire
September 28, 2023
11:00 pm ET
Accesswire
10:45 pm ET
Accesswire
7:30 pm ET
Accesswire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.